文献速递外周动脉疾病

PROMISE I:LimFlow系统经皮深静脉动脉化治疗无选择慢性肢体威胁性缺血的12个月结果

PROMISE I: Early feasibility study of the LimFlow System for percutaneous deep vein arterialization in no-option chronic limb-threatening ischemia: 12-month results.
PubMed 文献 · J Vasc Surg · 2021-05-18

PROMISE I早期可行性研究纳入32例无选择CLTI且既往建议大截肢患者,用LimFlow系统行pDVA,31例(97%)手术成功。30天、6个月、12个月无截肢生存率分别为91%、74%、70%;6个月和12个月伤口完全愈合或愈合中分别为67%和75%。16例(52%)再干预,多数涉及支架段近端动脉流入道。

要点

  • LimFlow pDVA技术成功率高(31/32,97%),12个月无截肢生存率70%。
  • 12个月伤口完全愈合或愈合中达75%,6个月为67%。
  • 52%患者需再干预,88%维护性再干预发生在术后3个月内。

核心结论

  • LimFlow pDVA系统治疗无选择CLTI技术成功率高,12个月无截肢生存率70%,伤口愈合比例75%,提示早期安全性和初步疗效。

研究设计与样本

  • 单臂早期可行性研究,纳入32例无选择CLTI且既往建议大截肢的患者,均不适合外科或腔内动脉血运重建。

主要发现

  • 31例(97%)手术成功,2例(6.3%)失访。
  • 30天、6个月、12个月无截肢生存率分别为91%、74%、70%。
  • 6个月和12个月伤口完全愈合或愈合中分别为67%和75%。
  • 16例(52%)接受再干预,其中14例(88%)维护性再干预在术后3个月内。
  • 再干预多数(12例,75%)涉及支架段近端动脉流入道,无支架内狭窄导致再干预。

关键数值与推荐

  • 无选择CLTI定义为不适合外科或腔内动脉血运重建。
  • 主要终点无截肢生存定义为无踝以上截肢且无全因死亡。

临床怎么用

  • 对于不适合常规血运重建的无选择CLTI患者,LimFlow pDVA可作为保肢选项,但需密切监测流入道并计划早期再干预。

局限性

  • 单臂早期可行性研究,样本量小(32例),2例失访,缺乏对照,需扩大研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We report the 6- and 12-month outcomes of the PROMISE I early feasibility study after treatment of no-option chronic limb-threatening ischemia (CLTI) with percutaneous deep vein arterialization (pDVA) using the LimFlow System. METHODS: Thirty-two patients with no-option CLTI, previously offered major amputation, were enrolled in this single-arm early feasibility study of the LimFlow pDVA System. No-option CLTI was defined as being ineligible for surgical or endovascular arterial revascularization. Patients were assessed for clinical status, pain, wound healing, and duplex ultrasound at 30 days, 6 months, and 12 months post-treatment. Primary endpoint analysis was amputation-free survival (AFS) at 30 days and 6 and 12 months. AFS was defined as freedom from above-ankle amputation of the index limb and freedom from all-cause mortality. Secondary endpoints evaluated included technical success of the procedure, and wound healing at 6 and 12 months. RESULTS: Of 32 enrolled patients, 31 (97%) were successfully treated with the LimFlow System at the time of the procedure, and two (6.3%) were lost to follow-up. The 30-day, 6-month, and 12-month AFS rates were 91%, 74%, and 70% respectively. The wound healing status of fully healed or healing was 67% at 6 months, and 75% at 12 months. Reintervention was performed in 16 patients (52%) with 14 (88%) of the maintenance reinterventions occurring within the first 3 months. The majority of reinterventions (n = 12; 75%), involved the arterial inflow tract proximal to the stented LimFlow circuit, and no in-stent stenoses were determined to have been the cause of reintervention. CONCLUSIONS: The LimFlow pDVA System was utilized in treating patients with no-option CLTI. A high technical success rate was observed, with a significant percentage of patients surviving free of major amputation at 12 months. These results suggest early safety and provide an initial assessment of the efficacy of the LimFlow pDVA System that supports the expansion of carefully executed studies to determine whether this is a viable option that can be used in this critically disadvantaged and growing patient population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Clair DG, Mustapha JA, Shishehbor MH, et al. PROMISE I: Early feasibility study of the LimFlow System for percutaneous deep vein arterialization in no-option chronic limb-threatening ischemia: 12-month results. J Vasc Surg. 2021. PMID: 34019990. doi:10.1016/j.jvs.2021.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。